HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Of J&J Consumer Biz Is Bigger, Not Bygone

This article was originally published in The Rose Sheet

Executive Summary

CFO Dominic Caruso notes the unit "has been an integral part of Johnson & Johnson for many years." Moreover, the consumer division is growing in importance as consumers look for more self-care options in health care and the firm expands its presence in emerging markets, capitalizing on high levels of brand recognition.

You may also be interested in...



J&J Beauty Acquisitions Help Propel Consumer Gains

J&J’s global consumer business dipped in reported terms but grew on an operational basis in fiscal 2016, driven by beauty and OTC. Company leadership noted the contributions of acquisitions, including NeoStrata dermocosmetics, Vogue hair-care brands and La Lumiere, which provided J&J with a light-therapy mask for treating acne.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel